Why Should You Invest In Ironwood Pharmaceuticals Inc (NASDAQ: IRWD)?

Best AI Stocks

In the latest trading session, 0.38 million Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) shares changed hands as the company’s beta touched 0.34. With the company’s most recent per share price at $3.62 changed hands at -$0.34 or -8.46% at last look, the market valuation stands at $580.10M. IRWD’s current price is a discount, trading about -333.7% off its 52-week high of $15.70. The share price had its 52-week low at $3.06, which suggests the last value was 15.47% up since then. When we look at Ironwood Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 2.02 million shares, with the 3-month average coming to 1.86 million.

Analysts gave the Ironwood Pharmaceuticals Inc (IRWD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IRWD as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.

Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) trade information

Instantly IRWD was in red as seen in intraday trades today. With action -19.62%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -18.17%, with the 5-day performance at -19.62% in the red. However, in the 30-day time frame, Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) is -2.55% down. Looking at the short shares, we see there were 12.08 million shares sold at short interest cover period of 6.67 days.

The consensus price target for the stock as assigned by Wall Street analysts is 8.5, meaning bulls need an upside of 57.41% from its recent market value. According to analyst projections, IRWD’s forecast low is 5 with 12 as the target high. To hit the forecast high, the stock’s price needs a -231.49% plunge from its current level, while the stock would need to soar -38.12% for it to hit the projected low.

Ironwood Pharmaceuticals Inc (IRWD) estimates and forecasts

Data shows that the Ironwood Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -44.06% over the past 6 months, a 101.28% in annual growth rate that is considerably higher than the industry average of 16.20%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -28.37%. The 2025 estimates are for Ironwood Pharmaceuticals Inc earnings to increase by 101.55%.

IRWD Dividends

Ironwood Pharmaceuticals Inc is expected to release its next quarterly earnings report in February.

Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.68% of Ironwood Pharmaceuticals Inc shares while 105.17% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 106.97%. There are 105.17% institutions holding the Ironwood Pharmaceuticals Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 14.5067% of the shares, roughly 22.88 million IRWD shares worth $149.16 million.

VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 13.6737% or 21.56 million shares worth $140.59 million as of 2024-06-30.

Among Mutual Funds, the top two as of Oct 31, 2024 were Pacer Small Cap U.S. Cash Cows 100 ETF and iShares Core S&P Smallcap ETF. With 11.05 shares estimated at $39.78 million under it, the former controlled 6.90% of total outstanding shares. On the other hand, iShares Core S&P Smallcap ETF held about 5.62% of the shares, roughly 9.0 shares worth around $32.39 million.